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Abstract: Inhibition of sclerostin is a therapeutic approach to lowering fracture risk in patients with 
osteoporosis. However, data from phase III randomized controlled trials (RCTs) of romosozumab, a first-
in-class monoclonal antibody that inhibits sclerostin, suggest an imbalance of serious cardiovascular 
events, and regulatory agencies have issued marketing authorizations with warnings of cardiovascular 
disease. Here we meta-analyze published and unpublished cardiovascular outcome trial data of 
romosozumab and investigate whether genetic variants that mimic therapeutic inhibition of sclerostin are 
associated with higher risk of cardiovascular disease. Meta-analysis of up to three RCTs indicated a 
probable higher risk of cardiovascular events with romosozumab. Scaled to the equivalent dose of 
romosozumab [210 mg/month; 0.09 g/cm2 higher bone mineral density (BMD)], the SOST genetic variants 
were associated with lower risk of fracture and osteoporosis (commensurate with the therapeutic effect of 
romosozumab), and with a higher risk of myocardial infarction (MI) and/or coronary revascularization and 
major adverse cardiovascular events (MACE). The same variants were also associated with increased 
risk of type 2 diabetes mellitus (T2D) and higher systolic blood pressure (SBP) and central adiposity. 
Taken together, our findings indicate that inhibition of sclerostin may elevate cardiovascular risk, 






Osteoporosis, a disorder characterized by low bone mass, is a common condition associated with 
considerable morbidity and mortality, particularly among postmenopausal women and the elderly (1). A 
range of therapeutics for osteoporosis is currently available, but these agents are plagued by poor 
adherence [fewer than 40% of patients prescribed oral bisphosphonates continue to take these 
medications after one year (2)], occurrence of rare but serious adverse events such as osteonecrosis of 
the jaw, high cost, and uncertainty regarding long-term efficacy (3). There is therefore a substantial 
demand for effective, safe and well-tolerated anti-osteoporotic therapies (4). 
 
Sclerostin, a glycoprotein encoded by the SOST gene, is a negative regulator of bone formation that is 
secreted by osteocytes. Sclerostin inhibits Wnt signaling, which leads to down-regulation of osteoblast 
development and function (5). Loss-of-function mutations in SOST lead to sclerosteosis, a rare autosomal 
recessive condition characterized by bone overgrowth (6). Similarly, van Buchem’s disease, another rare 
autosomal recessive condition with a phenotype similar to but generally milder than sclerosteosis, is 
caused by a deletion of a SOST-specific regulatory element (7). The discovery of functional variants in 
SOST as the underlying cause of these rare conditions of bone overgrowth nearly 2 decades ago led to 
the development of sclerostin inhibitors as a treatment for osteoporosis (8).  
 
Three anti-sclerostin monoclonal antibodies have been or are currently in clinical development (5): 
romosozumab and blosozumab for osteoporosis, and setrusumab -- currently in phase IIb for 
osteogenesis imperfecta and previously also studied in adults with hypophosphatasia (9). Despite phase 
II results showing increases in BMD (10), a biomarker used to evaluate the effect of anti-osteoporotic 
treatments, clinical development for blosozumab was halted in 2015, reportedly due to injection site 
reactions (11). Phase II and III RCTs have shown that romosozumab effectively increases BMD in both 
men and women, while also reducing vertebral and non-vertebral fracture risk in women (12–15). 
However, adverse event data reported in the phase III BRIDGE and ARCH trials (in men and post-
menopausal women, respectively) have suggested that romosozumab may be associated with an excess 
risk of cardiovascular events (14, 15). Concerns about the cardiovascular safety of romosozumab, and 
 
 
sclerostin-inhibition more generally, have previously been raised (8, 16–18), and in 2017 the US Food 
and Drug Administration (FDA) rejected an initial Biologics Licence Application for romosozumab due to 
concerns regarding cardiovascular adverse effects seen in the ARCH trial (19). Further licencing 
submissions were subsequently made to various regulatory agencies, including a resubmission to the 
FDA (20, 21). On 9 April 2019, the FDA approved romosozumab for the treatment of osteoporosis in 
postmenopausal women at high risk of fracture, with a boxed warning highlighting the risk of 
cardiovascular adverse events, and a post-marketing requirement to assess the cardiovascular safety of 
romosozumab (22). Further approvals have since been issued in Canada, Japan, and South Korea 
(including for both men and women in the latter two countries, and with no specific warning label in 
Japan). The European Medicines Agency (EMA) issued a refusal of an application to marketing 
authorization for romosozumab in June 2019, citing “an increased risk of serious effects on the heart or 
circulatory system” (23). In October 2019, following a re-examination procedure, the EMA recommended 
granting a market authorization (24), leading to approval by the European Commission in December 
2019, with a special warning relating to the risk of MI and stroke (25). 
 
A detailed appraisal of the cardiovascular effects of sclerostin inhibition by exploiting randomized data 
from orthogonal sources is therefore both timely and warranted, particularly given the discrepancy in 
opinions issued by regulatory agencies, and may assist in the evaluation of whether this class of drugs 
represents a rational and safe therapeutic strategy for the prevention of fracture. Naturally-occurring 
human genetic variation can serve as a proxy for therapeutic stimulation or inhibition of a drug target, 
presenting a valuable opportunity to assess the likely consequences of modifying a therapeutic target on 
both the intended therapeutic effects and target-mediated adverse drug reactions (26, 27). The 
application of this approach in a Mendelian randomization (MR) framework was previously shown to 
recapitulate known clinical effects of drug target modulation (28–30). In this study, we used this genetic 
approach to examine the effect of BMD-increasing alleles in the SOST locus (as a proxy for sclerostin 
inhibition) on the risk of bone fracture, osteoporosis, cardiovascular risk factors and disease (fig. S1), and 
complemented this with meta-analysis of cardiovascular data from RCTs of sclerostin inhibitors, to shed 





Risk of cardiovascular events in phase III RCTs of sclerostin inhibitors 
Romosozumab was the only sclerostin inhibitor with data from phase III RCTs. Four published phase III 
RCTs of romosozumab, including 11,954 individuals, were identified (table S1), of which three trials 
[BRIDGE (15), ARCH (14) and FRAME (13)] reported cardiovascular adverse event data (table S2). Only 
the BRIDGE (15) and ARCH (14) trials reported data on cardiac ischemic events and cerebrovascular 
events in their respective peer-reviewed publications. Unpublished data from the FRAME trial pertaining 
to these outcomes and data pertaining to MACE (a composite of cardiovascular death, nonfatal MI or 
nonfatal stroke) were extracted from US FDA Drugs Advisory Committee briefing documentation (31). 
 
Meta-analysis (using the Mantel-Haenszel method without continuity correction) of 25 events in 4,298 
individuals from two RCTs [BRIDGE (15) and ARCH (14)] identified that romosozumab (210 mg monthly) 
led to a higher risk of cardiac ischemic events as compared to the comparator [odds ratio (OR), 2.98; 95% 
confidence interval (CI), 1.18-7.55; P = 0.02; Fig. 1A]. Addition of the unpublished and non-peer reviewed 
FRAME data made available to the US FDA Drugs Advisory Committee brought the total number of 
cardiac ischemic events to 57 in 11,455 individuals, and resulted in a pooled OR of 1.54 (95% CI, 0.90-
2.64; P = 0.12; Fig. 1A). Corresponding estimates for cerebrovascular events were 27 events with OR of 
2.15 (95% CI, 0.94-4.92; P = 0.07) prior to US FDA meeting and 48 events with OR of 1.44 (95% CI, 
0.80-2.58; P = 0.22) afterwards. Estimates for MACE (130 events; OR 1.39; 95%, 0.98-1.98; P = 0.07) 
and serious cardiovascular events (183 events; OR 1.21; 95% CI, 0.90-1.63; P = 0.20) were directionally 
concordant with increased vascular risk arising from romosozumab treatment (Fig. 1B). Sensitivity 
analyses using the Peto-method showed similar results (fig. S2A and table S3), as did inclusion of an 
alternative number of serious cardiovascular events in the FRAME trial, using US FDA-sourced data (fig. 
S2B). 
 
Expression of SOST mRNA 
 
 
We identified two conditionally independent genetic variants in the SOST locus associated with BMD, 
rs7209826 [A>G, G-allele frequency in UK Biobank (UKBB) = 40%] and rs188810925 (G>A, A-allele 
frequency = 8%), from a recent large-scale genome-wide association study (GWAS) of estimated heel 
bone BMD (eBMD) (32). Expression of SOST across 53 human tissue types in the Genotype-Tissue 
Expression consortium was highest in arterial tissue (fig. S3; bone expression data not available). The 
minor alleles of rs7209826 (G-allele) and rs188810925 (A-allele) were both associated with lower 
expression of SOST mRNA in various human tissues, with the strongest associations with SOST 
expression for each variant identified in tibial artery (rs7209826: P = 1.4×10-8; 388 samples) and aorta 
(rs188810925; P = 7.6×10-6; 267 samples; fig. S4 and table S4). Colocalization analyses showed 
evidence of a shared causal variant driving the association with eBMD and SOST gene expression in 
tibial artery tissue (posterior probability of a shared causal variant of 74% in tibial artery for the rs7209826 
signal, after adjusting for other independent signals in the region; table S5 and fig. S5), with other arterial 
tissues underpowered to provide a reliable probability of colocalization. No valid sclerostin protein 
quantitative trait loci (pQTLs) could be identified. 
 
Association of rs7209826 and rs188810925 with BMD, osteoporosis, and fracture risk 
The minor alleles of both single-nucleotide polymorphisms (SNPs) were associated with higher eBMD in 
UKBB (32) (rs7209826: 0.04 g/cm2 [95% CI, 0.04-0.05; P = 2.3×10-36] per G allele and rs188810925: 0.07 
g/cm2 [95% CI, 0.05-0.08; P = 1.3×10-26] per A allele, fig. S6), and with higher lumbar spine BMD (LS-
BMD) (33) (rs7209826: 0.008 g/cm2 [95% CI, 0.005-0.01; P = 5.4×10-07] per G allele; rs188810925: 0.016 
g/cm2 [95% CI, 0.01-0.022; P = 4.3×10-07] per A allele, fig. S6). We subsequently scaled all further 
genetic estimates to the increase in LS-BMD seen with 12 months of romosozumab (210 mg monthly), 
equivalent to a 0.09 g/cm2 higher BMD (see Materials and Methods for a detailed description of scaling) 
(34).  
 
Scaled estimates from meta-analysis of rs7209826 and rs188810925 yielded a 57% lower risk of 
osteoporosis (OR, 0.43; 95% CI, 0.36-0.52; P = 2.4×10-18) and a 41% lower risk of sustaining a bone 
 
 
fracture (OR, 0.59; 95% CI, 0.54-0.66; P = 1.4×10-24; Fig. 2 and fig. S7). Associations were consistent 
across fracture sites (fig. S8).  
 
Association with cardiovascular events and cardiometabolic risk factors and diseases   
Next, we investigated the associations of the SOST variants with cardiovascular outcomes comparable to 
those used in the RCTs of romosozumab. In meta-analysis of scaled genetic estimates, the BMD-
increasing SOST variants associated with an 18% higher risk of MI and/or coronary revascularization 
(69,649 cases; OR, 1.18; 95% CI, 1.06-1.32; P = 0.003) and a 12% higher risk of MACE 119,032 cases; 
OR 1.12, 95% CI 1.03-1.21, P = 0.007; Fig. 3 and fig. S9). Using a broader and less specific definition of 
coronary heart disease (CHD), which included self-reported angina and chronic stable ischemic heart 
disease (up to 106,329 cases), the SOST variants associated with a 10% increased risk of disease (OR, 
1.10; 95% CI, 1.00-1.20; P = 0.04; Fig. 3 and fig. S9). 
 
Evaluation of cardiometabolic risk factors and diseases revealed that the BMD-increasing SOST variants 
associated with higher risks of hypertension (OR, 1.12; 95% CI, 1.05-1.20; P = 8.9×10-4) and T2D (OR, 
1.15; 95% CI, 1.05-1.27; P = 0.003; Fig. 4A).  
 
Consistent with the effect on hypertension, we found the SOST variants to be associated with 1.3 mmHg 
higher SBP (95% CI, 0.76-1.91; P = 5.9×10-6), but observed no effect on diastolic blood pressure (DBP; 
Fig. 4B). In addition, the SOST variants associated with 0.05 standard deviation (SD) units higher waist-
hip ratio adjusted for body mass index (WHRadjBMI; 95% CI, 0.02-0.08; P = 8.5×10-4), and, nominally, 
with higher serum triglycerides (9.58 mg/dl higher; 95% CI, 1.33-17.84 mg/dl; P = 0.02). We found no 
further associations (figs. S10-S13 and tables S6-S7). Sex-stratified analyses revealed that on average 
the point estimates for cardiometabolic risk factors and disease appeared stronger in women than men, 
however there was little statistical evidence of heterogeneity (table S8). Colocalization analyses of SBP 
and WHRadjBMI with eBMD were inconclusive due to low power (table S9), and a sensitivity analysis 
utilizing conditionally independent SOST variants from a more recent GWAS of eBMD (35) yielded 
 
 
comparable results (figs. S14-S15). An exploratory phenome-wide association analysis of 1,074 binary 
outcomes in UKBB did not reveal any further suggestive associations (fig. S16).  
 
Triangulation of randomized controlled trials and human genetics 
Triangulation refers to the integration of results from orthogonal approaches to study design, where each 
such approach has different sources of potential bias, to arrive at more reliable answers (36, 37). If the 
results from such approaches all support the same conclusion, this bolsters our confidence in the finding. 
To this end, we first performed fixed-effect meta-analysis of 337 clinical fractures in 11,273 individuals 
from two RCTs with fracture outcome data [FRAME (13) and ARCH (14), table S10], and identified that 
romosozumab (210 mg monthly) led to a 32% lower risk of clinical fracture as compared to comparator 
(hazard ratio 0.68; 95% CI, 0.55-0.85; P = 6.0×10-4; Fig. 5 and fig. S17) at 12 months. This compared 
well to the scaled genetic estimate, using the two SOST variants, of a 41% lower risk of fracture (Fig. 5). 
Evidence from treatment trials [up to three romosozumab phase III RCTs (14, 15)] and human genetics 
(two SOST variants) demonstrated an increased risk of coronary events (Fig. 5), indicating that this 
adverse effect is likely real and target-mediated.  
 
Finally, we compared the estimates of our SOST-specific instrument with those of a recent MR study 
evaluating the causal effect of genetically-predicted eBMD on risk of T2D and CHD (38). Scaling to the 
same difference in eBMD (an increase of 0.14 g/cm2 in eBMD), we found that estimates for the SOST-
specific instrument were very similar to those of the eBMD-instrument for both T2D and CHD (fig. S18). 
This suggests that the associations of our instrument with risk of T2D and CHD are consistent with the 
overall effect of BMD on these cardiometabolic outcomes, and reduces the likelihood of the SOST 
associations with disease arising due to locus-specific pleiotropy. 
 
Discussion 
Using data from human genetics and randomized interventional trials, we have shown that sclerostin 
inhibition leads to higher BMD and lower risk of osteoporosis and fractures, but also a higher risk of CHD. 
Although prior phase III RCTs of sclerostin inhibition by romosozumab suggested an increased risk of 
 
 
adverse cardiac events (14, 15), it remained possible that the finding was due to chance owing to the low 
number of events. With the addition of data that had not undergone peer review, made available by the 
sponsors of romosozumab to the US FDA in January 2019, the cumulative estimate for cardiac ischemic 
events attenuated. Thus, data from clinical trials support a probable but not unambiguous excess risk of 
cardiac disease arising from treatment with romosozumab. Our genetic analysis, which includes up to 
106,329 CHD cases, shows that the excess risk of CHD from sclerostin inhibition is likely to be real, and 
supports regulatory bodies’ addition of a warning for cardiovascular events to romosozumab labeling. Our 
findings also suggest that the excess risk of coronary events related to inhibition of sclerostin is driven, at 
least in part, by an increase in cardiovascular risk factors with an established etiological role in CHD, 
including adiposity, blood pressure, and T2D.  
 
Given the high short-term mortality associated with some types of fragility fracture -- up to 25% mortality 
in the 12 months following a hip fracture (39) -- a careful assessment of the potential risks versus benefits 
is warranted, weighing the merits of lower fracture and fracture-related morbidity and mortality against the 
potential harm from higher risk of metabolic and vascular disease. Clinical trials of romosozumab suggest 
that the reduction in relative risk of fracture (32%) is greater than the increased relative risk of coronary 
events (18%); however, such estimates relate to relative risks versus absolute risks, with absolute risks 
being more clinically meaningful, and furthermore, the reported relative risks do not take into account the 
differential impact that each disease has on an individual’s quality of life (as may be necessary to 
estimate the “benefit-risk” of a therapeutic).The use of human genetics in this context may pose a 
translational challenge in estimating the expected effects of a therapy in both relative and absolute terms: 
For example, genotype approximates prolonged or lifetime exposure, whereas a clinical trial is typically of 
considerably shorter duration (40).  
 
We did not observe statistical evidence of heterogeneity according to sex in our genetic analyses, a 
finding which is supported by romosozumab’s comparable effect on BMD in men and women in clinical 
trials (15). It is, however, notable that the genetic estimates for CHD, blood pressure, and T2D tended to 
be of greater magnitude in women than men. These findings emphasize that, despite limiting 
 
 
romosozumab’s label in the U.S. and Europe to only women (women being at relatively lower risk of 
vascular disease than men), treatment may still lead to an increase in vascular risk among women. 
 
There are several lines of evidence that support the findings of our study. Sclerostin is expressed in 
cardiovascular tissues (41, 42), supporting a potential biological role for this protein in these tissue types. 
In observational studies, higher concentrations of circulating sclerostin are associated with a higher risk of 
cardiovascular disease together with increased cardiometabolic risk factors such as hypertension, T2D 
and central adiposity (43–48). In contrast to our genetic findings, these data suggest that lowering of 
sclerostin may confer protection from cardiovascular disease; however, observational studies also show 
that osteoporosis and lower BMD are associated with lower sclerostin (49, 50) — suggesting that 
increasing sclerostin would lead to higher BMD. We know this to be spurious given the well-established 
effects of therapeutic sclerostin inhibition on BMD. Furthermore, recent investigations of BMD show that 
the observational association with risk of CHD and the corresponding estimate from MR analyses are 
directionally opposite (38), making observational associations of bone density and vascular disease 
unreliable. More recent evidence has suggested that sclerostin may be up-regulated in the vasculature in 
response to vascular calcification, as part of a regulatory process aimed at counteracting such 
calcification (18), whereas murine studies have implicated sclerostin in adipocyte metabolism (51) and the 
development of atherosclerosis, aortic aneurysm, and hemopericardium (52, 53). Although these human 
and animal data serve as evidence for the biological plausibility of sclerostin inhibition altering 
cardiovascular risk, extrapolating findings from animal models of disease to humans is plagued by failures 
of translation (54), and observational studies of humans can be influenced by sources of error. This is 
why studies using a randomized design in humans provide more reliable evidence on causation (37). 
 
Elucidation of whether adverse effects are on- or off-target is critical (8) because on-target effects would 
mean that any drug under development in the same class, such as a sclerostin inhibitor, would be 
expected to share a similar adverse effect profile, such as higher risk of vascular events. Our genetic data 
provide strong evidence in support of target-mediated adverse effects of sclerostin inhibition on coronary 
events. Sclerostin exerts its effects on bone as an inhibitor of the Wnt-signaling pathway -- a pathway 
 
 
also previously linked to vascular calcification (55–57) -- by binding to the Wnt co-receptor low density 
lipoprotein receptor-related protein (LRP) 5 and 6 (58). Protein-coding mutations in both LRP5 and LRP6 
have been linked to alterations in BMD and cardiometabolic risk profiles, including insulin resistance, 
dyslipidemia, hypertension, and CHD (59, 60), which supports our findings of altered cardiometabolic 
disease in carriers of SOST variants.  
 
Concerns of cardiovascular safety have also plagued other anti-osteoporotic agents. Odanacatib, a 
cathepsin K inhibitor developed for the treatment of osteoporosis, was not developed further after 
demonstrating reduced fracture risk in phase III trials because of an increased risk of stroke (61). We did 
not identify strong associations of SOST variants with risk of stroke subtypes in our analyses, however 
the point estimates for both ischemic and hemorrhagic stroke had ORs > 1. With genetic lowering of 
sclerostin leading to elevations in SBP and WHRadjBMI, each of which plays a causal role in stroke (62, 
63), it is plausible that additional stroke cases could identify such an association. More broadly, 
genetically elevated BMD may exert a causal effect on risk of T2D and CHD (38). Other BMD-raising 
therapies such as denosumab or bisphosphonates have not shown an association with increased risk of 
cardiovascular events in clinical trials (64–66). Some reports (31) using network meta-analysis have 
suggested that the increased cardiovascular risk seen in the romosozumab-arm of the ARCH trial (14) 
may have been due to a cardioprotective effect of alendronate, a bisphosphonate used in the ARCH 
control arm. However, meta-analyses of RCTs of bisphosphonates have shown that the effect of 
bisphosphonates on risk of cardiovascular events is null (65, 66), arguing against this hypothesis. In 
addition, this would not explain the imbalance seen in the placebo-controlled BRIDGE trial (15), nor would 
it account for our genetic findings.  
 
The approach to exploiting human genetics to validate target-mediated effects is well-established (28–
30). In our study, we selected variants associated with reduced expression of SOST and increased BMD 
as proxies for the effect of sclerostin inhibition. We validated the effects of the SOST genetic variants on 
risk of osteoporosis and bone fracture (including fracture across several sites), and leveraged a large 
number of CHD cases -- a more than 1,800-fold increase over the number of cases reported in phase III 
 
 
trials of romosozumab (13–15). Our approach also facilitated identification of potential mechanisms and 
mediators that may drive this excess coronary risk. For example, the association of SOST variants with 
central adiposity, SBP, and T2D has not been previously reported and if not measured in a clinical trial 
such associations cannot be readily explored.  
 
Our study is subject to several limitations. First, we examined life-long effects of genetic variants, which 
are not necessarily representative of the effects seen with pharmacological perturbation of shorter 
duration later in life. Second, the common, non-coding variants that we use in this study have not been 
conclusively linked to altered sclerostin protein expression or function. A recent GWAS of circulating 
serum sclerostin (67) reported three trans-pQTLs but found that SNPs in the SOST locus were only 
nominally associated with serum sclerostin concentration. The authors speculated that this finding may 
suggest that SOST SNPs influence BMD and fracture risk by altering local sclerostin activity in bone, 
independently of serum sclerostin. Further studies of larger sample size will be needed to explore the 
effect of genetic variants in the SOST locus on circulating sclerostin. We attempted to investigate the 
effects of the trans-pQTLs, but found that they were unlikely to be reliable instruments. Nonetheless, the 
validity of our variants as suitable genetic instruments to mimic treatment with an inhibitor of sclerostin is 
supported by their association and colocalization with SOST mRNA expression across various tissue 
types, and with relevant therapeutic outcomes including BMD, fracture risk, and osteoporosis. Third, 
although rare mutations in SOST have been linked to an extreme BMD phenotype indicating the 
presence of an allelic series of common and rare trait-associated alleles (68), we were not able to 
evaluate the effect of loss-of-function coding variants in SOST, primarily due to the relative scarcity of 
such variants in the general population. The most common predicted loss-of-function SOST variant in the 
gnomAD database (69) has a minor allele frequency of 9.2×10-6, with no homozygotes reported. 
Increased cardiovascular risk has not been reported in individuals with Mendelian disorders of absent or 
low sclerostin expression such as van Buchem disease or sclerosteosis. Reasons for this may include a 
shortened life-expectancy observed in some of these patients (for instance due to raised intracranial 
pressure) (70) and having not been examined for cardiovascular disease specifically. Deep phenotyping, 
including comprehensive cardiovascular evaluation, of individuals with loss-of-function variants in SOST 
 
 
would likely be of value (71, 72). Fourth, in scaling the allelic estimates to match the effect of 
pharmacologic inhibition of sclerostin, we assumed that the effect of the variants on BMD and the 
outcomes of interest is linear in nature. Observational evidence suggests that the association between 
BMD and cardiovascular risk is inversely linear, with lower BMD and osteoporosis associated with higher 
cardiovascular risk (38, 73, 74); however, this is directionally opposite to the evidence from MR studies, 
which suggests that higher BMD is causally associated with higher cardiovascular risk (38), and therefore 
poses challenges in testing the assumption of linearity in the genetic associations. Nevertheless, the 
same approach to scaling allelic estimates has also been applied in studies similar to ours, and is an 
established approach in MR (28, 29, 75). Finally, we note that the effect estimates derived from the meta-
analysis of RCTs of sclerostin inhibition provide only weak evidence of an adverse effect on cardiac 
disease. At the time of initiating this study, prior to the US FDA meeting of January 2019, the unpublished 
data from the FRAME trial had not been made available. Our meta-cumulative plot shows the evolving 
nature of the vascular disease effects of sclerostin: prior to the US FDA hearing, the OR of cardiac 
ischemic events was 2.98 (95% CI, 1.18-7.55) with 25 events. Addition of non-peer-reviewed vascular 
disease events, which more than doubled the number of cases, led to a halving of the effect estimate (OR 
1.54) with the 95% CI including the null (95% CI, 0.90, 2.64). Thus the data from clinical trials are 
consistent with a potential elevated risk of vascular disease arising as an adverse consequence of 
treatment with sclerostin inhibition, but the trial evidence is not conclusive. Network meta-analysis may 
suggest that the excess risk from rosomozumab could have arisen due to a protective effect of 
alendronate (31), however this is not supported by large-scale meta-analyses of bisphosphonates. 
Irrespective, our genetic estimates are consistent with an excess risk of cardiac events being real and 
target-mediated. Further, the pattern of associations of SOST variants not only with CHD, but also with 
risk factors with an established causal role in CHD including adiposity, blood pressure, and T2D make it 
implausible that these genetic findings have arisen by chance. 
 
Our findings support the US FDA and EMA’s addition of a warning for cardiovascular risk to 
romosozumab’s label (22), and indicate that other therapies inhibiting sclerostin are also likely to exert 
similar cardiovascular effects. With the benefit of hindsight, our analyses could have identified this 
 
 
potential for an increased cardiovascular risk prior to initiating clinical development of romosozumab (and 
other sclerostin inhibitors). This information may have been incorporated into trial design, particularly for 
directly evaluating the effect of romosozumab on cardiovascular outcomes and risk factors in adequately-
powered RCTs. The post-marketing surveillance mandated by the US FDA consisting initially of a five-
year observational feasibility study (22), while important, is subject to multiple sources of bias (76, 77). 
Our results therefore emphasise the utility of large-scale human genetic data in characterizing target-
mediated effects to inform preclinical drug target validation (27, 68, 78). 
 
In conclusion, our results warrant a rigorous assessment of the effect of romosozumab (and other 
sclerostin inhibitors in clinical development) on cardiovascular disease and cardiometabolic risk factors. 
This adds valuable information to whether pharmacological inhibition of sclerostin should be pursued as a 
therapeutic strategy for the prevention of fracture.   
 
 
Materials and Methods 
Study design. We performed two major analyses to investigate whether treatment with sclerostin 
inhibitors is likely to adversely impact on cardiovascular disease. First, we meta-analyzed cardiovascular 
outcomes data from RCTs of sclerostin inhibitors. Second, we examined the effect of BMD-increasing 
alleles in the SOST gene (encoding sclerostin) on the risk of therapeutic and cardiovascular outcomes. 
An overview of the genetic analysis is shown in fig. S1.  
 
Study population. We examined individual-level genotypic and phenotypic data for 502,617 subjects in 
UKBB, a population-based cohort based in the United Kingdom. In addition, we included data from a 
further two European-ancestry cohorts: Partners HealthCare Biobank (PHB; up to 19,132 subjects) and 
Estonian Biobank (EGCUT; up to 36,074 subjects). Trans-ethnic replication was attempted in China 
Kadoorie Biobank (CKB; up to 81,546 subjects). Further detail pertaining to each cohort is described 
below. 
 
UK Biobank (UKBB). UKBB is a prospective study of more than 500,000 British individuals recruited 
from 2006 to 2010 and aged between 45 and 69 (79). Phenotypic information available includes self-
reported medical history as ascertained by verbal interview with a medical professional at enrolment, 
hospital-derived electronic health record (EHR) data, including International Classification of Diseases, 
ninth and tenth revision (ICD-9 and ICD-10) codes and Office of Population and Censuses Surveys 
(OPCS-4) procedure codes, and an extensive set of physical measurements. Genotypic data (see below 
for detail) is available for 488,377 individuals, of whom 487,409 have imputed genotype data.  
For the purposes of this study, we excluded all samples indicated to have poor quality genotypes by 
UKBB (on the basis of high sample heterozygosity and missingness), and further excluded individuals 
that had: reported non-white or mixed ethnicity at any point during follow-up; withdrawn their consent for 
participation; >10 third degree relatives; putative sex chromosome aneuploidy; sex mismatches 
(comparing genetically determined vs. self-reported sex, and comparing between assessments); ethnicity 
mismatches (mismatches between genetically determined and self-reported ethnicity for white British 
individuals, and any ethnicity mismatches between assessments). We reviewed pairwise genetic 
 
 
relatedness between individuals and excluded one individual per pair of individuals with an estimated 2nd 
degree or closer relatedness [equivalent to a kinship coefficient of greater than 0.0884 (80)]. After 
applying these filters, 423,766 subjects remained. Baseline characteristics of participants in UKBB are 
shown in table S11. 
 
Genotyping in UKBB. Genotyping, quality control (QC) and imputation were performed centrally by UKBB, 
and details are fully described elsewhere (79). Briefly, genotype data are available for 488,377 
individuals, 49,950 of whom were genotyped using the Applied Biosystems UK BiLEVE Axiom Array by 
Affymetrix [containing 807,411 markers (81)].  The remaining 438,427 individuals were genotyped using 
the Applied Biosystems UK Biobank Axiom Array by Affymetrix (containing 825,927 markers). Both arrays 
were specifically designed for use in the UKBB project and share ~95% of marker content. Phasing was 
done using SHAPEIT3, and imputation was conducted using IMPUTE4. For imputation, the Haplotype 
Reference Consortium (HRC) panel (82) was used wherever possible, and for single nucleotide 
polymorphisms (SNPs) not in that reference panel, a merged UK10K + 1000 Genomes reference panel 
was used. SNPs were imputed from both panels, but the HRC imputation was preferentially used for 
SNPs present in both panels. Both SNPs selected as instruments in this study demonstrated high 
imputation quality in UKBB (info scores of 0.98 and 0.95 for rs7209826 and rs188810925, respectively).  
 
Study outcomes and definitions in UKBB. Fracture status was based on an affirmative answer to the 
question “Have you fractured/broken any bones in the last 5 years?” at either baseline or at follow-up. 
Individuals were designated as missing if they answered “Do not know” or “Prefer not to answer” at 
baseline and at all follow-up occasions. All remaining individuals were designated as controls. An 
identical definition has been used in recent GWAS of BMD and fracture (32, 83), and the use of self-
reported fracture has previously been validated (84). Individuals who reported having sustained a fracture 
were asked “Which bone(s) did you fracture/break?”, and given a list of options to choose from (including 
ankle, leg, hip, spine, wrist, arm, and other bones). For the purposes of our analysis, we grouped these 
into upper limb (wrist, arm), lower limb (ankle, leg, hip), vertebral (spine), and other fractures. 
 
 
Individual values for SBP and DBP and the definition of hypertension were derived using the same 
method as in a recent GWAS for blood pressure performed in UKBB (85). We derived the mean SBP and 
DBP for each subject from two blood pressure measurements performed at baseline. For subjects with 
only a single measurement available, we used this single value. We then adjusted these values for blood 
pressure-lowering medication use by addition of 10 and 15 mmHg to DBP and SBP, respectively, for 
subjects who had reported taking blood pressure medication at baseline (86). Individuals were coded as 
having hypertension if they had an adjusted SBP of 140 mmHg or higher, DBP of 90 mmHg or higher, or 
reported use of antihypertensive medication.  
To create phenotypes for body mass index (BMI) and WHRadjBMI, we followed steps consistent with 
those followed in the GIANT consortium (87–89). Baselines measures of BMI, waist circumference and 
hip circumference were used. We first divided waist circumference by hip circumference to calculate the 
WHR, and then regressed WHR on BMI, sex, age at time of assessment and (age at time of 
assessment)2, whereas BMI was regressed on sex, age at time of assessment and (age at time of 
assessment)2. Next we performed rank inverse normalization on the resulting residuals from the 
regressions. These normalized residuals (for BMI and WHRadjBMI) were used for performing allelic 
association testing.  
We included two definitions for CHD: an inclusive CHD phenotype including angina and other forms of 
chronic CHD, and a more specific phenotype of MI and/or coronary revascularization only. Both of these 
definitions were derived from those used in a recent GWAS of CHD conducted in UKBB by the 
CARDIoGRAMplusC4D consortium (90). 
Detailed definitions for all binary outcomes analyzed in UKBB (and not specifically defined above) are 
given in table S12.  
 
Ethical considerations. The UKBB project was approved by the North West Multi-Centre Research Ethics 
Committee and all participants provided written informed consent to participate. This research has been 




Partners HealthCare Biobank (PHB). We identified patients with relevant phenotype information and 
genotype data from the PHB (91, 92), a biorepository of consented patient samples at Partners 
HealthCare hospitals in the Boston area of Massachusetts. The PHB maintains blood and DNA samples, 
clinical records and genotype data from consented patients. Patients are recruited in the context of 
clinical care appointments and electronically. All patients who participate in the PHB are consented for 
their samples to be linked to their clinical information for the use in broad-based research. 
A total of 19,136 patients of European ancestry were genome-wide genotyped in PHB, including 8,868 
males and 10,268 females with age at recruitment ranged from 19 to 102 (mean=59.4, median=62, 
SD=16.61). For these patients, electronic health records were available for extracting the following 
phenotypes: fracture, osteoporosis, CHD, MI and/or coronary revascularization, T2D, BMI, HDL-
cholesterol, LDL-cholesterol, triglycerides, and hypertension. We subset these patients according to the 
phenotype information availability for each genetic association analysis (See “Study outcomes and 
definitions in PHB” below). 
 
Genotyping in PHB. DNA samples from whole blood and genome-wide genotyping were done for 25,582 
patients. Genotyping were done with Illumina Multi-Ethnic Genotyping Array (first batch), Expanded Multi-
Ethnic Genotyping Array (second batch), and Multi-Ethnic Global BeadChip (third batch), all of which 
were designed to capture the global diversity of genetic backgrounds (N of genotyped variants: 1,416,020 
– 1,778,953). 
Pre-imputation QC was performed on each genotyping batch separately as follows: we removed SNPs 
with genotype missing rate > 0.05 before sample-based QC; excluded samples with genotype missing 
rate > 0.02, absolute value of heterozygosity > 0.2, or failed sex checks; removed SNPs with missing rate 
> 0.02 after sample-based QC. To merge genotyping batches for imputation and analyses, we performed 
batch QC by removing SNPs with significant batch association (p-value < 1.0x10-6 between different 
batches). 
 
Since the PHB samples have diverse population backgrounds, we performed Hardy-Weinberg equilibrium 
test (p-value < 1.0x10-6) for SNP-based QC after extracting samples of European ancestry (see below). 
 
 
We also performed relatedness tests by identifying pairs of samples with π > 0.2 and excluding one 
sample from each related sample pair (560 samples excluded). All QC were conducted using PLINK v1.9 
and R software.  
We extracted samples with European ancestry based on principal component analysis (PCA) with 1000 
Genomes Project reference samples. To identify patients of European ancestry, we first performed PCA 
on LD-pruned dataset merged with 1000 Genomes Project reference samples labeled with 5 distinct 
super-populations (European [EUR], African [AFR], East Asian [EAS], admixed American [AMR], and 
South Asian [SAS]). Then, we used the top 4 PCs to build a random forest classifier trained on 1000 
Genomes Project reference samples with super-population labels. Finally, we applied the trained random 
forest classifier to identify patients of European ancestry from PHB (with predicted probability of European 
ancestry > 0.9).  
Genotype imputation was performed on the QCed patients of European ancestry with a 2-step pre-
phasing/imputation approach. We used Eagle2 for the pre-phasing and minimac3 for imputation, with a 
reference panel from 1000 Genomes Project phase 3. 
 
Study outcomes and definitions in PHB. We extracted relevant phenotype information from electronic 
health records for the patients with imputed genome-wide genotype data. The phenotype definitions and 
number of samples are described in table S13.  
 
Ethical considerations in PHB. The PHB maintains blood and DNA samples from consented patients seen 
at Partners HealthCare hospitals in the Boston area of Massachusetts. Patients are recruited in the 
context of clinical care appointments, and also electronically. Biobank subjects provide consent for the 




Estonian Biobank (EGCUT). The EGCUT is the population-based biobank containing longitudinal data 
and biological samples, including DNA, for 5% of the adult population of Estonia. The broad informed 
consent form signed by the participants of the biobank allows the Estonian Genome Center to 
continuously update their records through periodical linking to central electronic health record databases 
and registries. We studied the genotypic and phenotypic data of 51881 individuals and after removing 
relatives (PiHat >0.2), 36073 individuals (65% women, 35% men) with average age of 45 years were 
included for further analysis. For the CHD analyses in EGCUT, we only included participants not 
previously included in the CARDIoGRAMplusC4D consortium.  
 
Genotyping in EGCUT. Of all the studied biobank participants 33,155 have been genotyped using the 
Global Screening Array, 8137 HumanOmniExpress beadchip, 2640 HumanCNV370-Duo BeadChips and 
6861 Infinium CoreExome-24 BeadChips from Illumina. Furthermore, of 2056 individuals’ whole genomes 
have been sequenced at the Genomics Platform of the Broad Institute. 
Sequenced reads were aligned against the GRCh37/hg19 version of the human genome reference using 
BWA-MEM1 v0.7.7; PCR duplicates were marked using Picard (http://broadinstitute.github.io/picard) 
v1.136, and the Genome Analysis Toolkit (GATK) v3.4-46 applied for further processing of BAM files and 
genotype calling. All insertion-deletions (indels) in the Variant Call Format (VCF) were normalized and 
multiallelic sites split using bcftools (https://samtools.github.io/bcftools/bcftools.html). The following 
genotypes were set to missing: genotype quality <20, read depth >200, allele balance <0.2 or >0.8 for 
heterozygous calls. The GATK’s Variant Quality Score Recalibration (VQSR) metric was used to filter 
variants with a truth sensitivity of 99.8% for SNVs and of 99.9% for indels. Furthermore, variants with 
inbreeding coefficient <-0.3, quality by depth <2 for SNVs and <3 for indels, call rate < 95%, or Hardy-
Weinberg equilibrium (HWE) P-value <1×10-6 were excluded. 
The genotype calling for the Illumina microarrays was performed using Illumina’s GenomeStudio V2010.3 
software. The genotype calls for rare variants on the GSA array were corrected using the zCall software 
(version May 8th, 2012). After variant calling, the data was filtered using PLINK (v.1.90) by sample (call 
rate >95%, no sex mismatches between phenotype and genotype data, heterozygosity < mean +-3 SE) 
and marker-wise (HWE p-value >1×10-6, call rate >95%, and for the GSA array additionally by Illumina 
 
 
GenomeStudio GenTrain score >0.6, Cluster Separation Score >0.4). Before the imputation, variants with 
MAF <1% and C/G or T/A polymorphisms as well as indels were removed, as these genotype calls do not 
allow precise phasing and imputation. The genotype data obtained on all of the arrays were separately 
phased using Eagle2 (v. 2.3) and imputed using the BEAGLE (v. 4.1) software implementing a joint 
Estonian and Finnish reference panel (93). 
 
Study outcomes and definitions in EGCUT. We tested the associations of rs7209826 and rs188810925 
with fracture (ICD-10 codes S52.5, S82.6, S22.3, S42.2, S52.6, S22.4, S42.0, S82.8, S72.0, S71.1, 
S52.1, S32.0, S52.0, S82.4, S82.3, S72.1, S82.5, S22.0, S82.1, S82.7, S82.2, S82.0, S32.5, S32.2, 
S42.3, S52.2, S52.3, S42.4, S72.3, S52.8, S22.2, S52.4, S42.1, S72.2, S72.4, S32.1, S22.1, S12.2, 
S32.7, S32.8, S32.4, S82.9, S32.3, S52.9, S12.1, S42.8, S12.7, S72.8, S42.7, S72.9, S22.5, S72.7, 
S12.0, S42.9), osteoporosis (ICD-10 codes M80 and M81), the prevalent coronary artery disease (ICD-10 
codes I20, I21, I22, I23, I24, I25), infarction  (ICD-10 codes I21, I22, I25.2) and SBP (measured at 
participant recruitment). For all of the outcome variables with an exception of cardiovascular disease we 
considered prevalent case statuses reported at recruitment and individuals with records of diagnosis 
codes reported in the electronic registries before the recruitment. For the outcome of cardiovascular 
disease, we considered only prevalent cases reported at recruitment.  
 
Ethical considerations in EGCUT. Analyses in EGCUT were approved by the Ethics Review Committee of 
the University of Tartu (243T-12). 
 
China Kadoorie Biobank (CKB). The CKB is a prospective cohort of 512,713 adults aged 30-79 years. 
Individuals were recruited between the years of 2004-2008 from 5 urban and 5 rural regions across 
China, as previously described (94). Baseline information was collected via detailed questionnaire 
(including demographic/ lifestyle factors and medical history) and physical measurements (which included 
anthropometry, blood pressure and spirometry). A non-fasting blood sample was taken and separated 
into plasma and buffy-coat fractions for long-term storage. Long-term follow up is through electronic 
linkage of each participant’s unique national identification number to the Chinese national health 
 
 
insurance system, and established regional registries for death and disease. Health insurance reports 
include detailed information (e.g. disease description, International Statistical Classification of Diseases 
and Related Health Problems, 10th Revision [ICD-10] code, and procedure or examination codes) about 
each hospital admission. Vascular disease events have been reviewed and standardized by clinicians. 
 
Genotyping in CKB. 102,783 CKB participants were genotyped using 2 custom-designed Affymetrix 
Axiom arrays including up to 800K variants, optimized for genome-wide coverage in Chinese populations. 
Stringent QC included SNP call rate>0.98, plate effect p>10‑6, batch effect p>10-6, HWE p>10-6 (combined 
10df Chi-Sq test from 10 regions), biallelic, MAF difference from 1KGP EAS < 0.2, sample call rate >0.95, 
heterozygosity<mean+3SD, no chrXY aneuploidy, genetically-determined sex concordant with database, 
and exclusion of recent immigrants to each study area as identified by region-specific principal 
component analysis, resulting in genotypes for 532,415 variants present on both array versions in 94,592 
individuals. Imputation into the 1,000 Genomes Phase 3 reference (EAS MAF>0) using SHAPEIT version 
3 and IMPUTE version 4 yielded genotypes for 10,276,634 variants with MAF >0.005 and info >0.3. 
rs188810925 was not imputed (1KGP EAS MAF=0), rs7209826 was imputed with info=0.986, MAF=0.30. 
 
Study outcomes and definitions in CKB. Outcomes, phenotypes and transformations are defined in table 
S14. Disease endpoints are for hospitalisations, from electronic linkage to the national health insurance 
system. Phenotypes were measured either at baseline or in a subset of individuals at the second 
resurvey of ~5% of the CKB cohort. 
 
Ethical considerations in CKB. Ethical approval for CKB was obtained jointly from the University of 
Oxford, the Chinese Centre for Disease Control and Prevention (CCDC) and the regional CCDC from the 
10 study areas. 
 
Transethnic replication. We attempted transethnic replication in CKB. In 21,547 individuals with eBMD 
measurements available, the rs7209826 variant showed no evidence of association (beta = 0.0016 g/cm2; 
SE = 0.001; P = 0.14) and strong evidence of heterogeneity with the corresponding eBMD estimate in 
 
 
UKBB (P-heterogeneity = 1.35×10-28; fig. S19). A regional analysis showed no evidence of a suitable 
genetic instrument (fig. S20). Transethnic replication in a large East Asian biobank (CKB) could not be 
reliably performed owing to a lack of association of SOST variants with BMD, however there was a lack of 
association with CHD and other outcomes in CKB (table S15). This provides an opportune means to 
illustrate that the multiple cardiometabolic risk factor and disease associations identified in the European 
datasets, wherein genetic variants of SOST act as valid instruments for inhibition of sclerostin, did not 
arise as a consequence of horizontal pleiotropy (in other words, the genetic associations did not arise 
through a mechanism other than that which operates through inhibition of sclerostin). The absence of 
suitable instruments in CKB does not imply that pharmacological inhibition of sclerostin will not be an 
effective therapeutic strategy for raising BMD in non-European populations. 
 
Genome-wide association study (GWAS) consortia. We supplemented data from UKBB with 
summary-level data from 9 GWAS consortia, including data for BMD [both ultrasound-derived estimated 
heel-bone BMD (32) (eBMD) and dual-energy x-ray absorptiometry (DXA)-derived BMD measured at 
various anatomical sites (33)], CHD and MI (95), stroke (96), atrial fibrillation (97), T2D (98) and 
glycaemic traits (99, 100), serum lipid fractions (101), anthropometric traits (88, 89), and chronic kidney 
disease (102, 103). Where available, we selected data pertaining to analyses conducted in European-
ancestry individuals. Further details on each consortium are provided in table S16. 
  
GEFOS consortium. Detailed descriptions pertaining to measurement of eBMD and BMD are provided 
elsewhere (32, 33). Estimates for eBMD were provided in g/cm2 units (32). Estimates for DXA-derived 
BMD across three anatomical sites (lumbar spine (LS-BMD), femoral neck (FN-BMD) and forearm (FA-
BMD)) were provided in SD units (33). We converted these estimates to g/cm2 units using an estimate of 
the pooled population SD for each of these three measures (0.18 g/cm2, 0.14 g/cm2 and 0.07 g/cm2 for 
LS-BMD, FN-BMD and FA-BMD, respectively) in the GEFOS consortium (33). 
 
Genetic instrument selection and validation. A recent large-scale GWAS for eBMD, conducted in 
142,487 individuals (32), identified two conditionally independent (r2=0.13 among European ancestry 
 
 
individuals in UKBB) genetic variants in the SOST locus associated with eBMD: rs7209826 (A>G, G-allele 
frequency in UKBB = 40%) and rs188810925 (G>A, A-allele frequency = 8%). Both SNPs are located 
~35kb downstream from SOST and fall within or near a 52kb area that contains the van Buchem disease 
deletion (fig. S21), a region previously shown to affect SOST expression in human bone (7). Recent 
functional evidence has also shown that SNPs in this area (one of which, rs7220711, is in high LD 
[r2=0.99] with rs7209826) regulate SOST expression via differential transcription factor binding (104). 
Previous MR studies have also made use of non-coding variants with an effect on gene expression as 
proxies for pharmacologic modulation of the same target-gene (29, 30, 105, 106). 
We extracted estimates for these two SNPs (rs7209826 and rs188810925) from GWAS consortia listed in 
table S16. For GWAS datasets that did not include these variants, we selected proxy variants in high LD 
(r2>0.9) with our selected SNPs using HaploReg (107). We set an r2 threshold of >0.9 (in European 
ancestry individuals) for selection of suitable proxies. We identified 14 SNPs to be in high LD (r2=0.99) 
with rs7209826. Of these 14, we selected rs7220711 as a proxy for rs7209826 based on high LD (r2=0.99 
in European ancestry populations), availability across most consortia, and prior functional evidence 
linking rs7220711 to SOST expression (104). In addition, we validated the effect of rs7220711 on various 
measures of BMD as being comparable to that of rs7209826 (fig. S22). There were no suitable proxies 
(r2>0.9) for rs188810925. 
We examined the associations of rs7209826 and rs188810925 (and their selected proxies) on DXA-
derived measures of BMD measured at specific body sites (LS-BMD, FN-BMD, and FA-BMD), using data 
from the largest GWAS to date for these phenotypes (33). We next examined the effect of these variants 
on SOST mRNA expression in various human tissues in the Genotype-Tissue Expression (GTEx) project 
dataset (108). 
 
Study outcomes. Specific definitions used in each cohort are specified above. We first tested the 
association of rs7209826 and rs188810925 with key efficacy outcomes, i.e., fracture risk and risk of 
osteoporosis (both defined as a combination of self-reported outcomes and International Classification of 
Diseases, ninth and tenth revision (ICD-9 and ICD-10) codes).  
 
 
We selected coronary disease as the primary outcome of interest, given the association with cardiac 
ischemic events reported in a previous RCT of romosozumab (14). We examined the association of the 
BMD-increasing alleles of rs7209826 and rs188810925 with risk of MI and/or coronary revascularization 
(including self-reported and ICD-9/ICD-10 codes for MI, coronary artery bypass graft surgery and/or 
percutaneous transluminal coronary angioplasty) and a broader composite of all CHD (including all codes 
for MI and/or coronary revascularization, plus self-reported and ICD-9/ICD-10 codes for angina and 
chronic stable ischemic heart disease; see tables S12-S14 for specific codes included).  
Next, we investigated the association of the SOST variants with further outcomes and traits in two tiers: 
firstly, we examined risk of MACE (a composite of MI and/or coronary revascularization, stroke, or death 
from either) and all stroke [analogous to the ‘MACE’ and ‘cerebrovascular events’ outcomes studied in 
RCTs of romosozumab] and association with cardiovascular risk factors previously shown to play a 
causal role in CHD including: hypertension, T2D, SBP, DBP, BMI, WHRadjBMI, low-density lipoprotein 
(LDL) cholesterol, triglycerides, fasting insulin and glycated hemoglobin (HbA1c). Secondly, we evaluated 
an exploratory group of outcomes and traits to identify further putative associations including: ischemic 
stroke, hemorrhagic stroke, peripheral vascular disease, atrial fibrillation, heart failure, chronic kidney 
disease, aortic aneurysm, aortic stenosis, high-density lipoprotein (HDL) cholesterol, fasting glucose and 
serum creatinine-estimated glomerular filtration rate (eGFR).  
 
Statistical analyses. We derived cohort-specific SNP effect estimates from participants in the 4 
prospective cohorts. Estimates [log(OR) and the standard error of log(OR) for binary outcomes and beta 
and the standard error of beta for quantitative traits] for the per-allele effect of these variants on disease 
outcomes and quantitative traits were aligned to the BMD-increasing alleles (as per the effect of 
therapeutic sclerostin inhibition), and scaled to an increase in BMD equivalent to that reported with 
romosozumab treatment (see below). Estimates in each cohort were derived as described below.  
 
UKBB. The genotype-outcome association analyses in UKBB were performed using SNPTEST v2.5.4. 
We used an additive frequentist model (using “-frequentist 1”) and included sex, age at baseline, 
 
 
genotyping array (a binary variable), and the first 15 principal components as covariates in all analyses. 
We accounted for genotype uncertainty by using “-method expected”. 
 
PHB. Linear (for continuous phenotype) or logistic regression (for case-control binary phenotype) was 
used to test associations between SNPs rs188810925 and rs7209826 and phenotypes of interest using 
PLINK 1.9. For phenotypes without residual inverse rank normalization, we adjusted for sex, age at 
assessment, age squared, genotype batches and 15 principal components in the regression model. For 
phenotypes with residual inverse rank normalization, we did not adjust for any covariates in the 
regression model. 
 
EGCUT. We calculated the effect estimates for the two SNPs using logistic regression and adjusting for 
age, sex and 15 principal components. All associations were tested under an additive model using glm 
function with R software (3.3.2). 
 
CKB. To avoid ascertainment biases, unless otherwise specified, controls for binary endpoints were 
restricted to a 72,795 subset who had been randomly-selected for genotyping (~28k of genotyped 
samples were selected on the basis of incident CVD or COPD disease events). Covariates were as 
specified in table S14. All analyses used release version 15 of the CKB database and were performed 
using SAS software (version 9.3; SAS Institute, Inc). 
 
Scaling of allelic estimates. Similar to other studies using genetic variants to estimate the effects of drug 
target modulation (28, 75), we scaled allelic estimates pertaining to risk of osteoporosis, fractures, 
cardiometabolic outcomes and quantitative traits to an increase in BMD equivalent to that reported in a 
phase II RCT of 12 months of 210 mg romosozumab monthly (34). This corresponds to the dose 
evaluated in phase III RCTs of romosozumab, and represents a 0.09 g/cm2 increase in LS-BMD in 
postmenopausal women (34). We selected LS-BMD as the reference phenotype as this was the only 
BMD phenotype for which we had genetic data (33) and clinical trial data (34) in the same units of 
measurements (g/cm2). To do this, we derived the allelic effect estimates (in SD units) for the association 
 
 
of rs7209826 and rs188810925 with LS-BMD from a previous large-scale GWAS of LS-BMD (33) (0.046 
and 0.09 SD units, respectively). Since these estimates were reported in SD units, we first converted 
these standardized estimates to g/cm2 units by using the pooled (median) SD of LS-BMD as reported in 
the same study (one SD = 0.18 g/cm2). We then multiplied the SD-units effect estimates by this value, to 
derive estimates in g/cm2 units (rs188810925: 0.016 g/cm2; rs7209826: 0.008 g/cm2). Next, we derived a 
scaling factor for each SNP by dividing the increase in LS-BMD arising from treatment with 210 mg 
romosozumab monthly for 12 months (0.09 g/cm2) by the allelic effect estimate for LS-BMD [scaling 
factors: rs188810925 = 5.52; rs7209826 = 10.84)]. All per-allele effect estimates [log(OR) and the 
standard error of log(OR) for binary outcomes; beta and the standard error of beta for quantitative traits] 
were subsequently multiplied by these scaling factors to estimate the effects expected with 12 months of 
romosozumab (210 mg monthly). 
 
Meta-analysis of scaled allelic estimates. We meta-analysed scaled estimates from the prospective 
cohorts with (scaled) estimates from GWAS consortia for equivalent outcomes using inverse-variance 
weighted fixed-effect meta-analysis. We predefined a p-value threshold of <0.05 for the association with 
CHD given the association of sclerostin inhibition with cardiac ischemic events in prior RCTs (14, 15). For 
the first tier of outcomes and traits [MACE, all stroke and cardiovascular risk factors previously shown to 
play a causal role in CHD including: hypertension, T2D, SBP, DBP, BMI, WHRadjBMI, LDL cholesterol, 
triglycerides, fasting insulin and glycated hemoglobin (HbA1c)], we used a Bonferroni adjusted p-value 
threshold of < 0.004 (adjusting for a cumulative 13 tests), and for the second tier [including ischemic 
stroke, hemorrhagic stroke, peripheral vascular disease, atrial fibrillation, heart failure, chronic kidney 
disease, aortic aneurysm, aortic stenosis, HDL cholesterol, fasting glucose and serum creatinine-
estimated glomerular filtration rate (eGFR)], an adjusted p-value threshold of < 0.002 (adjusting for a 
cumulative 24 tests). The R-package METAFOR was used for performing all meta-analyses of scaled 
allelic estimates (109). Fixed-effect meta-analyses were used in all instances. Cochran’s Q test and the I2 
statistic were used to evaluate heterogeneity for all meta-analyses performed (see table S7).  
 
 
Sensitivity analyses. To evaluate the robustness of our instrument selection approach, we investigated 
the concordance of our findings with those of an alternative set of SOST instruments. We extracted 
conditionally independent SOST variants from a more recent GWAS of eBMD by Morris et al. (35), which 
included 426,824 individuals as compared to the 142,487 used in the GWAS by Kemp et al. (32), the 
latter being the primary data source for instrument derivation in this manuscript (of note, the datasets 
were overlapping). Using Morris et al. (35), two alternative SNPs were identified as most strongly 
associating with eBMD, rs2741856 and rs7217502. Both variants were in high or moderately high LD with 
the two variants derived from Kemp et al. (32) used in the current manuscript (r2=0.98 between 
rs7209826 and rs7217502 and r2=0.60 between rs188810925 and rs2741856). We compared 
associations of a SOST instrument using the 2 SNPs identified from Morris et al. (35) to our instrument 
(derived from Kemp et al. (32)) with various measures of BMD (fig. S14) and with major outcomes of 
interest (osteoporosis, fracture, and MI and/or coronary revascularization; fig. S15). We used the same 
scaling and meta-analysis approach for the two variants identified from Morris et al. (35) as we used for 
Kemp et al. (32), described above, using the LS-BMD estimate for each variant (fig. S14) to scale the 
allelic estimates relating to the major outcomes of interest. 
 
Sex-specific analyses. In light of the indication for romosozumab in the US (in women only), we 
performed additional sex-specific sensitivity analyses for all associated outcomes from the combined 
sexes analysis. Sexual heterogeneity was evaluated using Cochran’s Q test and the I2 statistic. 
 
Colocalization analyses. We used coloc, a Bayesian modelling approach (110), to estimate the posterior 
probability of shared causal variant(s) driving associations in pairs of traits (colocalization). We assessed 
colocalization of eBMD and tissue-specific SOST mRNA expression between conditionally independent 
eBMD signals in the SOST locus (those pertaining to rs7209826 and rs188810925) by first applying 
conditional analysis using the GCTA-COJO statistical suite (111), using genotype data from UKBB as an 
LD reference panel. We conditioned all datasets on rs2523161 (an independent eBMD-associated variant 
~600Kb from SOST), on either rs7209826 or rs188810925, and on any further independent eQTLs 
identified in specific tissues. We ran coloc on 400-kb and 2-Mb regions centred on each independent lead 
 
 
eBMD-associated SNP, and used the default priors. We investigated colocalization between eBMD and 
SOST gene expression in various tissues, SBP, and WHRadjBMI. Colocalization analyses where 
PP3 + PP4 < 0.8 were considered to be underpowered to detect colocalization (112, 113). Visual 
assessment of colocalization was performed using the LocusCompareR R library (114). For adequately 
powered colocalization analyses, we considered a PP4 > 0.8 as being consistent with colocalization 
between the two traits, although lower thresholds have recently been proposed (115–118). 
  
Protein quantitative trait loci (pQTL) analysis. We sought to investigate whether lower circulating 
sclerostin protein concentration is also associated with an increased risk of cardiometabolic diseases. For 
this analysis, we used genetic variants associated with circulating sclerostin protein as reported in a 
recent GWAS of this trait (67). Three trans-pQTLs (and no cis-pQTLs) were reported (two, rs215226 and 
rs7241221, meeting genome-wide significance of P < 5 × 10−8, and one (rs1485303) suggestive at P = 
7.70 × 10−8). We first evaluated the effect of these variants on various measures of BMD to confirm that 
the variants had a robust and appropriate effect on these biomarkers, before investigating their effects on 
clinical outcomes of interest.  
For one variant (rs1485303), we found that the sclerostin-lowering allele was associated with lower 
eBMD. This suggests that this variant is likely primarily lowering BMD through non-sclerostin-related 
mechanisms, leading to secondary lowering of sclerostin concentration in response to a reduced BMD. 
This is in keeping with the bi-directional relationship between circulating sclerostin and BMD as shown by 
Zheng et al. (67). The closest gene to rs1485303, TNFRS11B, encodes osteoprotegerin, a natural 
inhibitor of RANK ligand (RANKL). RANKL is also the therapeutic target of denosumab, a monoclonal 
antibody indicated for the treatment of osteoporosis. These observations suggest that rs1485303 is 
unlikely to be a valid proxy for therapeutic inhibition of sclerostin. For the remaining two variants, 
rs215226 (intronic to B4GALNT3) and rs7241221 (near GALNT1), a lack of robust association with LS-
BMD (P = 0.06 and 0.45, respectively) precluded further evaluation. Trans-pQTLs are vulnerable to 
potential confounding by horizontal pleiotropy, thereby potentially limiting confidence that the phenotypic 
associations of such SNPs are solely attributable to their effect on the protein of interest (sclerostin in our 
 
 
case). This is a central tenet of instrumental variable analysis (the so-called ‘exclusion restriction’ 
criterion).  
 
Phenome-wide association analysis. We extracted estimates relating to the association of rs188810925 
and rs7209826 with 1,074 binary outcomes (those with more than 200 cases available) from publicly 
available summary statistics generated by the Lee lab (available from: 
https://www.leelabsg.org/resources). All estimates were scaled to match the effect of romosozumab (210 
mg monthly for 12 months) on LS-BMD (0.09 g/cm2) and aligned to the BMD-increasing alleles. 
 
Meta-analysis of RCTs of sclerostin-inhibitors. We searched for all phase III RCTs performed for 
sclerostin inhibitors (romosozumab, blosozumab and setrusumab). We collected a record of trials 
conducted for sclerostin inhibitors from the websites of the agents’ developers 
(http://www.amgentrials.com/amgen/study.aspx; https://www.mereobiopharma.com/pipeline/bps-804-
setrusumab/), and supplemented this with further searches on clinical trials registries (ClinicalTrials.gov, 
EU Clinical Trials Register and International Clinical Trials Registry Platform) and PubMed (1966-
present), using the key-words (“sclerostin” OR “romosozumab” OR “AMG-785” OR “setrusumab” OR 
“blosozumab”) AND (“trial” OR “randomized controlled trial” OR “RCT” OR “randomised controlled trial”) 
for PubMed. One of the authors (J.B.) screened the titles and abstracts of all identified studies for 
eligibility; where doubt arose as to eligibility, the full paper was evaluated. Potentially eligible studies were 
reviewed with two senior authors (C.M.L. and M.V.H.). All published studies with available cardiovascular 
outcome data pertaining to a double-blind, comparator-controlled phase III RCT were eligible for 
inclusion. Our search strategy and results are summarised in table S17, with last search performed on 08 
November 2019. Seven phase III trials were identified (table S18), of which three trials met our criteria for 
inclusion in the meta-analysis. A PRISMA flow diagram is presented in fig. S23. Assessment of risk of 
bias for each eligible trial was completed using the Cochrane Risk of Bias tool (119), and is presented in 
fig. S24. We extracted each trial’s duration, blinding status, nature of the control intervention, and data 
pertaining to risk of ‘clinical fracture’ (a composite of nonvertebral fracture and symptomatic vertebral 
fracture) and risk of four cardiovascular outcomes (‘cardiac ischemic events’, ‘cerebrovascular events’, 
 
 
‘major adverse cardiovascular events’, and ‘serious cardiovascular events’) from the peer-reviewed 
publications of the trials. Where trials reported data pertaining to multiple phases (e.g. an initial blinded 
phase, followed by an open-label phase), only data pertaining to the blinded phase were extracted. We 
also incorporated unpublished data pertaining to the cardiovascular outcomes newly released by the 
sponsors of romosozumab for the US FDA Drugs Advisory Committee meeting in January 2019 (120), 
with the caveat that some of these data have not undergone peer-review (albeit adjudicated by two 
independent bodies — the Duke Clinical Research Institute [DCRI] and the Thrombolysis in Myocardial 
Infarction [TIMI] Study Group). Inclusion of these data in our analyses is indicated where appropriate. 
Data extracted from trial publications were cross-checked with the US FDA-reported data, where 
possible. If data for the same trial and outcome differed between the original publication and the US FDA-
reported data, we included data from the original publication in our primary analysis and performed further 
sensitivity analyses with inclusion of the US FDA-reported data. The risk of bias arising from selective 
publication of trials was deemed to be low - of the seven phase III trials of romosozumab we identified 
(table S18), three were unpublished. The largest unpublished trial included 294 participants (compared to 
the two largest, published phase III trials, ARCH and FRAME, totalling 4,093 and 7,180 participants, 
respectively). 
 
We then performed meta-analyses of cardiovascular outcome data at 12 months (corresponding to the 
duration of the blinded phase) from phase III RCTs using 210 mg romosozumab monthly for 12 months 
(since this was the only agent for which eligible RCTs were available, and also the standard dose and 
duration used across the eligible phase III trials), with ‘cardiac ischemic events’ as the primary outcome of 
interest, given the association with this outcome observed in a previous RCT of romosozumab (14). 
Further meta-analyses were performed for ‘cerebrovascular events’ and two composite outcomes: 
‘serious cardiovascular events’ (including cardiac ischemic events, cerebrovascular events, heart failure, 
cardiovascular death, non-coronary revascularization and peripheral vascular ischemic events not 
requiring revascularization) and ‘MACE’ (a composite of MI, stroke, or cardiovascular death). Meta-
analyses were performed by computing odds ratios and 95% confidence intervals for each cardiovascular 
outcome, using fixed-effect models. Cochran’s Q test was used to evaluate heterogeneity between trials. 
 
 
We set a prespecified p-value threshold of <0.05 for meta-analyses of the RCTs given the prior evidence 
for ischemic cardiovascular events seen in individual RCTs of romosozumab (14, 15)).  
All meta-analyses of RCT cardiovascular outcomes were performed according to the Mantel-Haenszel 
method without continuity correction. This method has been shown to perform relatively well when events 
are rare, and is also the default fixed-effect meta-analysis method recommended by the Cochrane 
collaboration (121–123). We performed additional sensitivity analyses using the Peto method, a fixed-
effect method shown to provide relatively unbiased results if within-trial intervention and control groups 
are of approximately equal size and if the effect size is modest (121, 122). Meta-analysis of fracture data 
was performed using inverse variance weighted fixed-effect meta-analysis of fracture risk at 12 months in 
the FRAME (13) and ARCH (14) trials (table S10). All meta-analyses of trial data were performed using 
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Fig. 1. Cumulative meta-analysis of cardiac ischemic events and meta-analysis of romosozumab 
and risk of cardiovascular events from phase III RCTs. (A) Meta-cumulative plot of cardiac ischemic 
events, with RCTs ordered by data availability. Each line represents the addition of a further trial to the 
meta-analysis. The dashed horizontal line separates RCTs with data that were peer-reviewed and 
available prior to the US FDA Drugs Advisory Committee meeting in January 2019 (ARCH and BRIDGE 
trials, with the meta-analyzed estimate highlighted in blue) from the FRAME trial. (B) Conventional meta-
analysis of data from phase III RCTs of romosozumab, including unpublished data released for the US 
FDA Drugs Advisory Committee meeting in January 2019 (indicated with red asterisk). Events represents 
number of events adjudicated per arm during initial 12-month double-blind period in each trial. The 
romosozumab group received 210 mg romosozumab monthly in all trials; comparator group received 
placebo (FRAME and BRIDGE trials) or 70 mg alendronate weekly (ARCH). Estimates were derived 
using the Mantel-Haenszel method. Boxes represent point estimates of effects. Lines represent 95% 
confidence intervals. OR, odds ratio; CI, confidence interval. 
 
Fig. 2. Scaled estimates and meta-analysis of BMD-increasing SOST variants with risk of 
osteoporosis and fracture. Estimates are scaled to match the effect of romosozumab (210 mg monthly 
for 12 months) on LS-BMD (0.09 g/cm2; see the Materials and Methods) and aligned to the BMD-
increasing alleles. 15,239 cases of osteoporosis and 53,074 cases of fracture were analyzed. See the 
Materials and Methods sections for outcome definitions. Boxes represent point estimates of effects. Lines 
represent 95% confidence intervals. OR, odds ratio; CI, confidence interval. 
 
Fig. 3. Scaled estimates and meta-analysis of BMD-increasing SOST variants with risk of MI and/or 
coronary revascularization, CHD, and MACE. Estimates are scaled to match the effect of 
romosozumab (210 mg monthly for 12 months) on LS-BMD (0.09 g/cm2; see the Materials and Methods) 
and aligned to the BMD-increasing alleles. MI and/or coronary revascularization includes codes pertaining 
to MI, coronary artery bypass graft surgery and/or percutaneous transluminal coronary angioplasty; up to 
 
 
69,649 cases were analyzed. CHD includes all codes pertaining to MI and/or coronary revascularization, 
plus codes for angina and chronic stable ischemic heart disease; up to 106,329 cases were analyzed. 
MACE includes codes pertaining to a composite of MI and/or coronary revascularization, stroke, or death 
from either; up to 119,032 cases were analyzed. Boxes represent point estimates of effects. Lines 
represent 95% confidence intervals. OR, odds ratio; CI, confidence interval. 
 
Fig. 4. Meta-analysis of BMD-increasing SOST variants and cardiometabolic risk factors. (A) 
Association with hypertension and T2D. (B) Association with quantitative traits plotted in SD units, with 
clinical units for each trait indicated in the column on the right. All estimates are scaled to match the effect 
of romosozumab (210 mg monthly for 12 months) on LS-BMD (0.09 g/cm2; see the Materials and 
Methods) and aligned to the BMD-increasing alleles. The significance threshold was set at 0.004 (see the 
Materials and Methods for details). Boxes represent point estimates of effects in odds ratio (A) or SD (B) 
units. Lines represent 95% confidence intervals. OR, odds ratio; CI, confidence interval; mmHg, 
millimetres of mercury; SD, standard deviations. 
 
Fig. 5. Inhibition of sclerostin and risk of fracture and cardiovascular events derived from meta-
analysis of phase III RCTs of romosozumab and human genetics. Fracture risk RCT estimate 
represents inverse variance weighted fixed-effect meta-analysis of estimates for hazard ratio of clinical 
fracture at 12 months (a composite of non-vertebral or symptomatic vertebral fracture) in the ARCH and 
FRAME trials. Coronary event risk RCT estimates represent fixed-effect meta-analysis (using the Mantel-
Haenszel method) of estimates for odds ratio of cardiac ischemic events in the ARCH and BRIDGE trials 
only [RCT Estimate (pre-FDA)] and if including unpublished FRAME trial data released for US FDA Drugs 
Advisory Committee meeting in January 2019 [RCT Estimate (post-FDA)]. Data pertaining to the MACE 
risk RCT estimates were solely sourced from the US FDA Drugs Advisory Committee meeting data. 
Scaled genetic estimates for fracture risk, coronary event risk, and MACE risk represent inverse variance 
weighted fixed-effect meta-analyses of the scaled allelic estimates for the odds ratio of fracture risk, MI 
and/or coronary revascularization, and MACE, respectively. All RCT estimates refer to the effect of 
romosozumab (210 mg monthly for 12 months) relative to comparator, and all genetic estimates are 
 
 
scaled to match the effect of romosozumab (210 mg monthly for 12 months) on LS-BMD (0.09 g/cm2 
increase). Boxes represent point estimates of effects. Lines represent 95% confidence intervals. RR, 
relative risk; CI, confidence interval. 
